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Recently, Baggio-Zappia et al. (2011) reported the ef-
fects of GB virus C (GBV-C) on interleukin (IL)-2 and 
interferon (IFN)-γ in CD4 and CD8 T cells. GBV-C coin-
fection was not associated with lower immune activation 
in human immunodeficiency virus (HIV)-positive indi-
viduals as measured by CD38 expression per cell and IL-2 
and IFN-γ expressing cells in their study. We agree with 
Baggio-Zappia et al. (2011) that “several factors, such as 
differences in the study populations, the stage of HIV in-
fection and the time of GBV-C acquisition, may account 
for the discrepant results reported by different research 
groups”. However, two major factors may confound inter-
pretation of the results reported by Baggio-Zappia et al. 
and provide the most likely explanation for the discrepant 
results observed between this study and previous reports 
(Maidana-Giret et al. 2009, Baggio-Zappia et al. 2011).
First, approximately 85% of the subjects studied were 
on potent combination antiretroviral therapy (cART) and 
had nondetectable HIV RNA levels in their plasma. cART 
lowers T cell activation, raises CD4 counts, decreases 
HIV VL and thus interferes significantly with other fac-
tors associated with HIV disease progression (Autran et 
al. 1997, Carcelain et al. 2001, Lederman 2001). Since the 
vast majority of subjects in the study of Baggio-Zappia 
et al. (2011) were effectively treated by cART, it is not 
surprising that GBV-C did not have an observed effect on 
the clinical variables studied (CD4, HIV VL etc.).
Secondly, Baggio-Zappia et al. (2011) froze the periph-
eral blood mononuclear cells (PBMCs) prior to conduct-
ing in vitro studies of activation, IL-2 and IFN-γ cytokine 
production. Freeze-thawing PBMCs can alter detection of 
both surface marker expression and T cell function (Kvarn-
strom et al. 2004, Mallone et al. 2011). By comparison, 
several groups found a reduction in CD38 on CD4 and/or 
CD8 T cells in HIV-infected subjects using fresh PBMCs 
(Bhattarai et al. 2011, Maidana-Giret et al. 2009). In addi-
tion, HIV entry (chemokine) receptors CCR5 and CXCR4 
are upregulated on CD4 and CD8 T cells following T cell 
activation (Smith et al. 2002). Three independent groups 
found reduced levels of CCR5 on CD4 cells using fresh, 
non-frozen PBMCs and one of these studies also found 
reduced levels of CXCR4 on CD4 cells (Nattermann et al. 
2003, Maidana-Giret et al. 2009, Schwarze-Zander et al. 
2010). Finally, IL-2 interactions with GBV-C have been 
demonstrated in vitro (George et al. 2003, Bhattarai 2011) 
and in vivo (Stapleton et al. 2009) using fresh, non-frozen 
cells for flow cytometry studies.
Since cART will lower detection of cell surface mark-
ers of T cell activation, making detection of a diminu-
tion by GBV-C more difficult to detect, and since frozen 
PBMCs can alter levels of T cell activation markers, we 
believe that the study of Baggio-Zappia et al. (2011) does 
not negate the prior studies that used fresh PBMCs to 
evaluate T cell activation. However, the results illustrate 
the need for more direct and thorough studies of GBV-C 
on T cell function in individuals with HIV-infection.
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REply
Comments in regards to 
Bhattarai and Stapleton’s letter
Recently, our group reported the findings of a study 
that evaluated the effect of GBV-C viremia on IL-2 and 
IFN-γ production in CD4, CD8 and γδ T cells and CD38 
expression in CD4 and CD8 T cells. Our results did not 
find an association of GBV-C viremia with lower immune 
activation in human immunodeficiency virus (HIV)-pos-
itive or GBV-C-hepatitis C virus (HCV) co-infected indi-
viduals (Baggio-Zappia et al. 2011). In agreement, other 
studies conducted with different cohorts of HIV-infected 
patients did not found a beneficial effect of GBV-C on 
the course of HIV disease  (Brumme et al. 2002, Quiros-
Roldan et al. 2002, Bjorkman et al. 2004). N Bhattarai 
and JT Stapleton point that the results found in the study 
are a result of the ART and to the use of frozen PBMCs to 
conduct the in vitro experiments.
We agree with N Bhattarai and JT Stapleton that ART 
lowers T cell activation, raises CD4 T cell counts, de-
creases HIV VL, and interferes significantly with other 
factors associated with HIV disease progression, as nu-
merous studies previously demonstrated  (Autran et al. 
1997, Carcelain et al. 2001, Lederman et al. 2001), how-
ever, in this study, all the patients presented a consider-
ing degree of immune activation, as demonstrated by the 
evaluation of CD38 activation marker, independent of the 
use of ART. In addition, in order to address if the lack 
of statistical significance was the use of ART, we per-
formed two analyses, considering HIV-treated and HIV-
non treated patients and we found the same results (data 
not shown). Interestingly, Antonucci et al. evaluated the 
relationship between GBV-C infection and response to 
antiretroviral therapy in a cohort of 400 HIV-infected pa-
tients found that those patients who were GBV-C infected 
presented a lower risk of HIV rebound when compared 
with those who were GBV-C negative, showing that an 
effect of the virus was observed in spite of the ART ther-
apy. In the same study, the authors found that the prob-
ability of achieving initial virological success or CD4 T 
cell count response after HAART did not differ between 
GBV-C negative and GBV-C positive subjects.
In our study (Baggio-Zappia et al. 2011) frozen (PB-
MCs was used to conduct the in vitro studies of activa-
tion, IL-2 and IFN-γ cytokine. As an experienced group in 
the methodology, we have already conducted experiments 
with fresh PBMCs and the same results were obtained. In 
addition to our experience, other studies demonstrated that 
cytokine release in vitro is not significantly different in 
fresh or cryopreserved PBMCs  (Friberg et al. 1994, Venet 
et al. 2010). Another point to be considered regarding CD38 
is that in the present study, we evaluated the quantitative 
expression of the immune activation marker, not only if 
the cells were expressing it, as performed in previous stud-
ies  (Maidana-Giret et al. 2009), and this could explain the 
differences of the results, besides the differences between 
chronically and early infected patients.
Our study has never had the intention to negate the 
prior studies; instead it adds new data that corroborate 
the need to conduct more detailed studies that consider 
the stages of the HIV infection and also, the role of the 
co-infection with other viruses such as HCV in the con-
text of the HIV disease.
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